A Biomarker Study of STA9090 in Castration-Resistant Prostate Cancer (CRPC) With Assessment of Androgen Receptor Pathway Signaling

Trial Profile

A Biomarker Study of STA9090 in Castration-Resistant Prostate Cancer (CRPC) With Assessment of Androgen Receptor Pathway Signaling

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2015

At a glance

  • Drugs Ganetespib (Primary) ; Dutasteride
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 01 Dec 2012 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 01 Mar 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 09 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top